Related Experiment Video
Updated: Aug 8, 2026
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Multiple CTL specificities against autologous HIV-1-infected BLCLs
P M Ahearne1, R A Morgan, M W Sebastian
1Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710.
Cellular Immunology
|March 1, 1995
Summary
Researchers developed a new method to study cellular immune responses to HIV-1. This approach uses HIV-1-infected B-lymphocyte cell lines (BLCLs) to better represent in vivo targets for analyzing T-cell responses.
Area of Science:
- Immunology
- Virology
- Cell Biology
Background:
- Cellular immune responses to Human Immunodeficiency Virus type 1 (HIV-1) are crucial but not fully understood.
- Previous studies on cytotoxic T-lymphocyte (CTL) specificities often used artificial constructs, limiting understanding of patient responses to autologous HIV-1-infected cells.
Purpose of the Study:
- To develop a more accurate in vitro model for studying patient cellular reactivity against HIV-1-infected cells.
- To characterize the nature of the cellular immune response elicited by autologous HIV-1-infected cells.
Main Methods:
- Utilized two strategies to enhance CD4 expression in B-lymphocyte cell lines (BLCLs).
- Infected enhanced BLCLs with multiple HIV-1 strains.
- Assessed recognition and lysis of HIV-1-infected BLCLs by autologous effector cells.
- Characterized the mediating cells (CD8+) and restriction (MHC Class I).
Main Results:
- HIV-1-infected BLCLs were successfully generated and recognized by autologous effector cells.
- Cytolytic specificities were directed against HIV-1 env, gag, and pol determinants.
- HIV-1-infected BLCLs elicited in vitro CTL responses mediated by CD8+ cells in an MHC Class I-restricted manner.
Conclusions:
- HIV-1-infected BLCLs serve as a more natural and representative in vivo cellular target model compared to existing systems.
- This model facilitates a more accurate analysis of CTL responses during HIV-1 infection and post-vaccination.
